Stay updated with breaking news from Paper Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be...
At #AGS22, @AmerGeriatrics and #geriatrics experts casts a wide net for social & scientific innovations shaping better care for us all as we age. http://ow.ly/H6OV50IZluC.
27.04.2022 - OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice LONDON, April 27, 2022 (GLOBE NEWSWIRE) - OKYO Pharma Limited (LSE: OKYO; OTCQB: ... Seite 1
Investegate announcements from OKYO Pharma Limited, Upcoming Presentations at Ophthalmic Conference